Pair page
HGH with IGF-1 DES
Mechanism-tag overlap and published literature for HGH and IGF-1 DES, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
hormonerecombinant-human-growth-hormonerhgh
igf-1-receptor-agonistmodified-proteinn-terminally-truncated-analog
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying HGH and IGF-1 DES have published these mechanism-level observations. Not a co-administration recommendation.
rhGH drives systemic IGF-1 axis via hepatic production; IGF-1 DES adds direct local receptor stimulation. Compounds all IGF-1-axis safety concerns (cancer risk, insulin resistance, organ growth). Only appropriate within a legitimate clinician-supervised framework for diagnosed GH deficiency; bodybuilding combinations are outside the evidence base.
Quick facts
HGH
IGF-1 DES
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2007 | HGH | Liu H, Bravata DM, Olkin I, Nayak S, Roberts B, Garber AM, Hoffman AR. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007;146(2):104-115. PMID: 17200260. (The most-cited independent appraisal of anti-aging rhGH.) PMID 17200260 | systematic review |
| 2020 | HGH | Johannsson G, Gordon MB, Højby Rasmussen M, Håkonsson IH, Karges W, Sværke C, Tahara S, Takano K, Biller BMK. Once-weekly somapacitan is effective and well tolerated in adults with GH deficiency: a randomized phase 3 trial. J Clin Endocrinol Metab. 2020;105(4):e1358-e1376. PMID:… PMID 32072187 | human trial, Phase 3 |
| 2000 | HGH | Mauras N, Attie KM, Reiter EO, Saenger P, Baptista J; Genentech, Inc Cooperative Study Group. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. J Clin Endocrinol Metab. 2000… PMID 11061517 | human trial |
| 2012 | HGH | Sävendahl L, Maes M, Albertsson-Wikland K, Borgström B, Carel JC, Henrard S, Speybroeck N, Thomas M, Zandwijken G, Hokken-Koelega A. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium… PMID 22259051 | human study |
| 2011 | HGH | Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML; Endocrine Society. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(6):1587-1609. PMID: 21543432. PMID 21543432 | human study |
| 2003 | HGH | Grinspoon S, Mulligan K; Department of Health and Human Services Working Group on the Prevention and Treatment of Wasting and Weight Loss. Weight loss and wasting in patients infected with human immunodeficiency virus. Clin Infect Dis. 2003;36(Suppl 2):S69-S78. PMID: 12652374. (… PMID 12652374 | human study |
| 1990 | HGH | Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, Mattson DE. Effects of human growth hormone in men over 60 years old. N Engl J Med. 1990;323(1):1-6. PMID: 2355952. (The landmark anti-aging reference.) PMID 2355952 | human study |
| 2026 | HGH | WADA. 2026 World Anti-Doping Code Prohibited List. Section S2 — Peptide hormones, growth factors, related substances and mimetics. World Anti-Doping Agency. (rhGH S2 prohibition and detection methods.) | regulatory / registry |
| 2021 | HGH | U.S. Food and Drug Administration. Skytrofa (lonapegsomatropin-tcgd) Prescribing Information. Ascendis Pharma. First approved 2021. | regulatory / registry |
| 2020 | HGH | U.S. Food and Drug Administration. Sogroya (somapacitan) Prescribing Information. Novo Nordisk. First approved 2020. | regulatory / registry |
| — | HGH | U.S. Food and Drug Administration. Genotropin (somatropin) Prescribing Information. Pfizer Inc. | regulatory / registry |
| — | HGH | U.S. Food and Drug Administration. Norditropin (somatropin) Prescribing Information. Novo Nordisk Inc. | regulatory / registry |
| 2002 | IGF-1 DES | Philipps AF, Kling PJ, Grille JG, Dvoráková S. Intestinal transport of insulin-like growth factor-I (IGF-I) in the suckling rat. J Pediatr Gastroenterol Nutr. 2002;35(4):539-544. PMID: 12394383. (Colostrum IGF-1 DES context.) PMID 12394383 | preclinical, in vivo |
| 1993 | IGF-1 DES | Tomas FM, Knowles SE, Chandler CS, Francis GL, Owens PC, Ballard FJ. Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in normal female rats. J Endocrinol. 1993;137(3):413-421. PMID: 8371077. (In vivo anabolic effects of IGF-1 DES vs native IGF-1.) PMID 8371077 | preclinical, in vivo |
| 1991 | IGF-1 DES | Ballard FJ, Knowles SE, Walton PE, Edson K, Owens PC, Mohler MA, Ferraiolo BL. Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I), des(1-3)IGF-I and IGF-II in rats. J Endocrinol. 1991;131(1):87-93. PMID: 1720984. PMID 1720984 | preclinical, in vivo |
| 1991 | IGF-1 DES | Williams ED, et al. Comparison of des(1-3)IGF-1 and IGF-1 in promoting wound healing. Growth Factors. 1991 context. (Wound-healing preclinical reference.) | preclinical, in vivo |
| 1989 | IGF-1 DES | Sara VR, Carlsson-Skwirut C, Bergman T, Jörnvall H, Roberts PJ, Crawford M, Håkansson LN, Civalero I, Nordberg A. Identification of Gly-Pro-Glu (GPE), the aminoterminal tripeptide of insulin-like growth factor 1 which is truncated in brain, as a novel neuroactive peptide. Bioche… PMID 2597159 | mechanism / discovery |
| 1988 | IGF-1 DES | Francis GL, Upton FM, Ballard FJ, McNeil KA, Wallace JC. Insulin-like growth factors 1 and 2 in bovine colostrum. Sequences and biological activities compared with those of a potent truncated form. Biochem J. 1988;251(1):95-103. PMID: 3401742. (Seminal characterization of IGFBP-… PMID 3401742 | mechanism / discovery |
| 1986 | IGF-1 DES | Sara VR, Carlsson-Skwirut C, Andersson C, Hall E, Sjögren B, Holmgren A, Jörnvall H. Characterization of somatomedins from human fetal brain: identification of a variant form of insulin-like growth factor I. Proc Natl Acad Sci USA. 1986;83(13):4904-4907. PMID: 3459178. (Original… PMID 3459178 | mechanism / discovery |
| 2026 | IGF-1 DES | WADA. 2026 World Anti-Doping Code Prohibited List. Section S2 — Peptide hormones, growth factors, related substances and mimetics. World Anti-Doping Agency. (IGF-1 and analogs class prohibition.) | regulatory / registry |
| 2005 | IGF-1 DES | U.S. Food and Drug Administration. Increlex (mecasermin) Prescribing Information. Ipsen Biopharmaceuticals. First approved 2005. (Context: FDA-approved recombinant native IGF-1 — different molecule from IGF-1 DES.) | regulatory / registry |
| 2003 | IGF-1 DES | LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett. 2003;195(2):127-137. PMID: 12767520. PMID 12767520 | research article |
| 2001 | IGF-1 DES | Musarò A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, Barton ER, Sweeney HL, Rosenthal N. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet. 2001;27(2):195-200. PMID: 11175789. (Foundational muscle-s… PMID 11175789 | research article |
| 1993 | IGF-1 DES | Sommer A, Maack CA, Spratt SK, Mascarenhas D, Tressel TJ, Rhodes ET, Lee R, Roumas M, Tatsuno GP, Flynn JA, et al. Molecular genetics and actions of recombinant insulin-like growth factor binding protein-3. Adv Exp Med Biol. 1993;343:265-277. PMID: 7515280. (IGFBP context.) PMID 7515280 | research article |
Related pair pages
More research context
Frequently asked
Have HGH and IGF-1 DES been studied together?
Researchers have published mechanistic-level co-administration discussion of HGH and IGF-1 DES. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do HGH and IGF-1 DES share?
HGH and IGF-1 DES do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of HGH and IGF-1 DES?
HGH: Approved (GHD, Turner, PWS, SHOX, ISS, CKD, AIDS wasting, SBS). IGF-1 DES: Not approved; research only. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on HGH and IGF-1 DES?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the HGH profile and the IGF-1 DES profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026